


**Amendments to the Claims**

Without prejudice or disclaimer, this listing of claims will replace all prior versions and listing of claims in this application.

1. (Original) Crystalline non-solvated 1-(4-(2-piperidinyloxy)phenoxy)-2-(4-methanesulfonylphenyl)-6-hydroxynaphthalene hydrochloride having an X-ray diffraction pattern which comprises the following peaks:  $15.2 \pm 0.1$ ,  $17.6 \pm 0.1$ ,  $18.6 \pm 0.1$  and  $24.1 \pm 0.1^\circ$  in  $2\theta$ ; when the pattern is obtained from a copper radiation source ( $\text{CuK}\alpha$ ,  $\lambda = 1.54056 \text{ \AA}$ ).
2. (Original) The salt of Claim 2 wherein said X-ray diffraction pattern further comprises the following peaks:  $16.9 \pm 0.1$ ,  $19.2 \pm 0.1$ ,  $21.3 \pm 0.1$  and  $21.6 \pm 0.1^\circ$  in  $2\theta$ .
3. (Amended) A method of treating endometriosis comprising administering to a patient in need thereof an effective amount of a compound of ~~either claim 1 or~~ claim 1 or 2.
4. (Amended) A method of treating uterine leiomyoma comprising administering to a patient in need thereof an effective amount of a compound of ~~either claim 1 or 2~~.
5. (Cancelled)
6. (New) A method of treating endometriosis comprising administering to a patient in need thereof an effective amount of a compound of claim 2.
7. (New) A method of treating uterine leiomyoma comprising administering to a patient in need thereof an effective amount of a compound of claim 2.

Respectfully submitted,



Gilbert T. Voy  
Attorney for Applicants  
Registration No. 43,972  
Phone: 317-276-2966

Eli Lilly and Company  
Patent Division/GTV  
Lilly Corporate Center  
Indianapolis, Indiana 46285

July 9, 2005